Last reviewed · How we verify
NCT02909283: DREAM²
Sickle Cell Anemia and Cerebral Microcirculation : Multimodal Exploration
trial testing Physical exams and blood analyzes in Sickle Cell Disease in 64 participants. Completed in 11 July 2017.
11 July 2017
Quick facts
| Lead sponsor | Imagine Institute |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 64 |
| Start date | 2 March 2015 |
| Primary completion | 11 July 2017 |
| Estimated completion | 11 July 2017 |
| Sites | 2 locations across France |
Drugs / interventions tested
- Physical exams and blood analyzes
Conditions studied
- Sickle Cell Disease — all drugs for Sickle Cell Disease →
Sponsor
Imagine Institute
Who can join
Adults 6 to 16, any sex, with Sickle Cell Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to evaluate determinants of cerebral oxygenation and perfusion at the microcirculatory level in children with sickle cell anemia (SCA) using combined novel investigational tools: Arterial Spin Labeling (ASL) perfusion MR (Magnetic Resonnance) imaging, brain Near Infra-Red Spectroscopy (NIRS) and red blood cell (RBC) rheological properties.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02909283
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sickle Cell Disease
Currently open trials in the same condition.
- NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
- NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
- NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
- NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
- NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting
Other Imagine Institute trials
Trials by the same sponsor.
- NCT07313098 — Longitudinal Assessment of Protein Markers in the Cerebrospinal Fluid of Patients With Central Nervous System Involvemen · not yet recruiting
- NCT07422454 — FACE.S-4-KIDS : A Deep Phenotyping Database of Craniofacial Anomalies During Development With 4 Pilot Projects · recruiting
- NCT06219421 — Automatic Phenotyping of Patients on 2D Photography · recruiting
- NCT06186856 — Epidemiological Data on Mast Cell Pathologies in France · recruiting
- NCT06380192 — Developmental and Epileptic Encephalopathy of Genetic Etiology: Natural History Through Reuse of Clinical Data · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02909283 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Imagine Institute
- Last refreshed: 14 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02909283.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing